Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Total Liabilities (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Total Liabilities for 16 consecutive years, with $80.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 3.13% to $80.3 million in Q4 2025 year-over-year; TTM through Nov 2025 was $80.3 million, a 3.13% increase, with the full-year FY2025 number at $80.3 million, up 3.13% from a year prior.
  • Total Liabilities was $80.3 million for Q4 2025 at Cryo Cell International, up from $78.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $107.0 million in Q1 2021 to a low of $50.6 million in Q1 2022.
  • A 5-year average of $70.1 million and a median of $70.9 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: surged 110.84% in 2021, then tumbled 52.73% in 2022.
  • Cryo Cell International's Total Liabilities stood at $56.5 million in 2021, then increased by 17.59% to $66.4 million in 2022, then grew by 8.79% to $72.3 million in 2023, then grew by 7.81% to $77.9 million in 2024, then increased by 3.13% to $80.3 million in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Total Liabilities are $80.3 million (Q4 2025), $78.0 million (Q3 2025), and $80.0 million (Q2 2025).